Integra Lifesciences Holdings Corp (NASDAQ: IART) has a price-to-earnings ratio of 59.20x that is above its average ratio. Additionally, the 36-month beta value for IART is 1.10. There are mixed opinions on the stock, with 4 analysts rating it as a “buy,” 5 rating it as “overweight,” 6 rating it as “hold,” and 0 rating it as “sell.”
The public float for IART is 65.06M and currently, short sellers hold a 7.02% ratio of that float. The average trading volume of IART on September 27, 2024 was 1.31M shares.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
IART) stock’s latest price update
Integra Lifesciences Holdings Corp (NASDAQ: IART)’s stock price has gone rise by 1.93 in comparison to its previous close of 17.14, globenewswire.com reported 2024-09-04 that PRINCETON, N.J., Sept. 04, 2024 (GLOBE NEWSWIRE) — Integra LifeSciences Holdings Corporation (NASDAQ: IART), a leading global medical technology company, announced today that Lea Knight, chief financial officer will present at the Morgan Stanley Healthcare conference on September 6, 2024 at 10:45am ET.
IART’s Market Performance
Integra Lifesciences Holdings Corp (IART) has seen a 0.00% fall in stock performance for the week, with a -14.86% decline in the past month and a -39.23% plunge in the past quarter. The volatility ratio for the week is 4.03%, and the volatility levels for the past 30 days are at 4.07% for IART. The simple moving average for the last 20 days is -4.31% for IART’s stock, with a simple moving average of -45.28% for the last 200 days.
Analysts’ Opinion of IART
Many brokerage firms have already submitted their reports for IART stocks, with Citigroup repeating the rating for IART by listing it as a “Sell.” The predicted price for IART in the upcoming period, according to Citigroup is $23 based on the research report published on July 30, 2024 of the current year 2024.
BTIG Research, on the other hand, stated in their research note that they expect to see IART reach a price target of $22. The rating they have provided for IART stocks is “Sell” according to the report published on July 30th, 2024.
Wells Fargo gave a rating of “Equal Weight” to IART, setting the target price at $25 in the report published on May 07th of the current year.
IART Trading at -20.95% from the 50-Day Moving Average
After a stumble in the market that brought IART to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -61.54% of loss for the given period.
Volatility was left at 4.07%, however, over the last 30 days, the volatility rate increased by 4.03%, as shares sank -14.15% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -44.80% lower at present.
During the last 5 trading sessions, IART remain unchanged, which changed the moving average for the period of 200-days by -57.67% in comparison to the 20-day moving average, which settled at $18.11. In addition, Integra Lifesciences Holdings Corp saw -59.89% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at IART starting from Mosebrook Jeffrey, who sale 1,191 shares at the price of $21.58 back on Aug 19 ’24. After this action, Mosebrook Jeffrey now owns 36,088 shares of Integra Lifesciences Holdings Corp, valued at $25,701 using the latest closing price.
ESSIG STUART, the Exec. Chairman of the Board of Integra Lifesciences Holdings Corp, purchase 52,641 shares at $28.49 during a trade that took place back on May 23 ’24, which means that ESSIG STUART is holding 487,922 shares at $1,499,979 based on the most recent closing price.
Stock Fundamentals for IART
Current profitability levels for the company are sitting at:
- 0.08 for the present operating margin
- 0.57 for the gross margin
The net margin for Integra Lifesciences Holdings Corp stands at 0.02. The total capital return value is set at 0.03. Equity return is now at value 1.47, with 0.60 for asset returns.
Based on Integra Lifesciences Holdings Corp (IART), the company’s capital structure generated 0.55 points at debt to capital in total, while cash flow to debt ratio is standing at 0.08. The debt to equity ratio resting at 1.2. The interest coverage ratio of the stock is 1.9.
Currently, EBITDA for the company is 297.59 million with net debt to EBITDA at 7.72. When we switch over and look at the enterprise to sales, we see a ratio of 2.01. The receivables turnover for the company is 5.64for trailing twelve months and the total asset turnover is 0.38. The liquidity ratio also appears to be rather interesting for investors as it stands at 3.39.
Conclusion
In conclusion, Integra Lifesciences Holdings Corp (IART) has seen bad performance in recent times. Analysts have a mixed opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
